A Dose Response Study of E6011 in Participants With Rheumatoid Arthritis Inadequately Responding to Methotrexate

NCT02960438 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

273

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: E6011
DRUG: Placebo

Sponsor

Eisai Co., Ltd.